<unk> , sold under the brand name Entresto, is a fixed-dose combination medication for use in heart failure. It consists of the neprilysin inhibitor<unk>  and the angiotensin receptor blocker valsartan. It is recommended for use as a replacement for an ACE inhibitor or an angiotensin receptor blocker in people with heart failure with reduced ejection fraction. Potential side effects include angioedema, kidney problems, and low blood pressure. The combination is sometimes described as an "angiotensin receptor-neprilysin inhibitor" (ARNi). This drug combination is normally not given to patients who have had a history of angioedema with an ACe inhibitor, because<unk>  acts as a Neprisilyn enzyme inhibitor and Valsartan is an angiotensin receptor blocker. It was approved for medical use in the United States and in the European Union in 2015. It was approved for medical use in Australia in 2016.
Sacubitril/valsartan
Telmisartan/amlodipine
Lisinopril/amlodipine
Amlodipine/atorvastatin
Olmesartan/amlodipine
Amlodipine/valsartan
Enalapril/hydrochlorothiazide
Amlodipine/benazepril